This Article Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (38) Citing Articles via Google Scholar Google Scholar Articles by Luce, B. R. Articles by Rentz, A. M. Search for Related Content PubMed PubMed Citation Articles by Luce, B. R. Articles by Rentz, A. M. Related Collections Managed Care Pharmaceuticals

Health Affairs, Vol 15, Issue 4, 168-176
Copyright © 1996 by Project HOPE

DataWatch

The view from managed care pharmacy

This stratified, national telephone survey of fifty-one managed care organizations concerns the perspectives of managed care pharmacy directors on pharmacoeconomics, disease management, and the roles of the pharmaceutical industry and the Food and Drug Administration (FDA). Respondents rated clinical effectiveness assessments as most useful, cost-effectiveness assessments second, and quality-of-life assessments as least useful. Peer-reviewed and industry literature were rated as equally important for decision making. Most plans would consider establishing a partnership with a drug company for disease management, if they have not already done so. Most plans (76 percent) support some form of FDA regulation of pharmacoeconomic claims. Conversely, 69 percent favor either no regulation (24 percent) or less stringent regulation (45 percent) than exists today.

                      What's this?

This article has been cited by other articles:

				P. J. Neumann, P. W. Stone, R. H. Chapman, E. A. Sandberg, and C. M. Bell The Quality of Reporting in Published Cost-Utility Analyses, 1976-1997 Ann Intern Med, June 20, 2000; 132(12): 964 - 972. [Abstract] [Full Text] [PDF]

				E. H. Morreim Quality of Life: Erosions and Opportunities Under Managed Care J. Law Med. Ethics, June 1, 2000; 28(2): 144 - 158. [PDF]